Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: a combined clinical-molecular pathological approach

Manuel Salto-Tellez, Ming-Sound Tsao, Jin-Yuan Shih, Sumitra Thongprasert, Shun Lu, Gee-Chen Chang, Joseph Siu-Kie Au, Teh-Ying Chou, Jong-Seok Lee, Yuan-Kai Shi, Ahmad Radzi, Jin-Hyoung Kang, Sang-We Kim, Soo-Yong Tan, James Chih-Hsin Yang

Research output: Contribution to journalArticlepeer-review

30 Citations (Scopus)

Abstract

Several randomized phase III studies in advanced stage non-small cell lung cancer (NSCLC) confirmed the superior response rate and progression-free survival of using epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor as first-line therapy compared with chemotherapy in patients with activating EGFR mutations. Despite the need for EGFR mutation tests to guide first-line therapy in East Asian NSCLC, there are no current standard clinical and testing protocols.
Original languageEnglish
Pages (from-to)1663-9
Number of pages7
JournalJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Volume6
Issue number10
DOIs
Publication statusPublished - Oct 2011

Keywords

  • Far East
  • Neoplasm Staging
  • Receptor, Epidermal Growth Factor
  • Antineoplastic Agents
  • Pathology, Molecular
  • DNA Mutational Analysis
  • Humans
  • Drug Resistance, Neoplasm
  • Asian Continental Ancestry Group
  • Individualized Medicine
  • Survival Rate
  • Lung Neoplasms
  • Treatment Outcome
  • Practice Guidelines as Topic
  • Carcinoma, Non-Small-Cell Lung
  • Mutation

Fingerprint Dive into the research topics of 'Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: a combined clinical-molecular pathological approach'. Together they form a unique fingerprint.

Cite this